041sek
-1,5 %
Date:2025-11-03Time:18:00:00Latest report:Q2-2025List:First NorthTicker:MODTX
Market Cap:49 msekEnterprise Value:52 msekNet Sales:- msekEarnings:-16,6 msekEmployees:0ISIN:SE0015987904

Ratios

10-year key figure history for Modus Therapeutics turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Modus Therapeutics with index and moving average MA50 and MA200.

Stockprice:0,41
MA50:0,80
MA200:1,30
Price/MA200:-68,7 %
RSI (14):38,9
Price/MA50:-49,4 %

Description

Modus Therapeutics operates in biotechnology. The product portfolio includes the drug candidate sevuparin. The company's focus is to develop sevuparin for patients with sepsis, septic shock and other conditions with systemic inflammation. In addition to its core business, it also offers service and related ancillary services. The business and related research are conducted with the largest presence in Sweden.

Biotechnology